• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Zicronapine     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatPiperazines, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAtypicalAntipsychoticsyago:Agent114778436yago:CausalAgent100007347yago:Drug103247620yago:DrugOfAbuse103248958yago:MajorTranquilizer103713736yago:Matter100020827yago:Medicine103740161yago:PhysicalEntity100001930yago:Piperazine103946814yago:PsychotropicAgent104017429drugyago:Sedative-hypnotic104166841yago:Sedative104166553yago:Substance100020090yago:Tranquilizer104470232yago:Vermifuge104528630yago:WikicatPiperazines New Facet based on Instances of this Class

Zicronapine (/zaɪˈkrɒnəpiːn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine. Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.